Missouri state court Judge Timothy Boyer granted final approval Friday in St. Louis to Bayer’s $7.25 billion (£5.5 billion) nationwide Roundup settlement, which could end nearly a decade of litigation for the German biotechnology company. Announced in February, the deal aims to resolve nearly all current and future U.S. claims that the weedkiller causes cancer, but excludes some pending federal lawsuits.
Bayer will pay into a fund annually for up to 21 years, contributing as much as $7.25 billion. Roundup users who have or later develop non-Hodgkin lymphoma can receive $10,000 to $165,000 based on frequency of use, timing of diagnosis and severity of illness.
Some attorneys argued that too little money was available. Boyer found the deal fair, reasonable and adequate, rejecting objections that individual claimants would get too little compared with earlier settlements. He said he wanted to avoid delaying payments to people already ill, including terminally ill patients who could otherwise wait an unknown number of years.
BBC News reported thousands of state and federal claims from people who said Roundup caused their cancer. The Guardian put the number at roughly 65,000 and said the claims involved use at home or at work.
In June, five months before the approval, the U.S. Supreme Court overturned a $1.25 million jury award to Missouri resident John Durnell. BBC News reported that Durnell blamed Roundup and its active ingredient, glyphosate, for his non-Hodgkin lymphoma. Durnell alleged years of exposure. The Supreme Court sided with Bayer in a 7-2 ruling, holding that federal pesticide law barred state-law failure-to-warn claims because federal regulations did not require a cancer warning on the label, undermining a key basis for many Roundup suits.
Christopher Seeger, a court-appointed lawyer for cancer patients who represents many plaintiffs, said the ruling made claims harder to pursue and Friday’s approval guaranteed compensation for claimants who had waited more than a decade. Bayer CEO Bill Anderson called the approval a decisive step toward limiting the company’s exposure to pending and future lawsuits. Bayer said litigation continued in about 200 excluded federal cases and credited the ruling with giving it strong defenses.
Bayer’s shares had fallen 46% since its $63 billion purchase in 2018 of Monsanto, which developed Roundup in the 1970s. Bayer previously paid roughly $10 billion to resolve claims, and juries in several states awarded users billions of dollars over years of costly litigation. In 2020, Bayer reached a $10.9 billion settlement covering much of the litigation but failed to win approval for a separate $1.25 billion proposal for future claims.
Bayer maintains that Roundup and glyphosate are safe and that decades of research found glyphosate does not cause cancer. Bayer and regulators including the U.S. Environmental Protection Agency dispute the World Health Organization’s International Agency for Research on Cancer’s 2015 classification of glyphosate as a probable human carcinogen.